A consolidated list of all the FDA approved medications during the month of April 2025.

  • Vanrafia (atrasentan)
    • For the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
  • Uplizna (inebilizumab-cdon) Expanded Indication
    • For adults living with Immunoglobulin G4-related disease (IgG4-RD).
  • Opdivo + Yervoy (ivolumab + ipilimumab) New Indication
    • in adult and pediatric patients age 12 or older with unresectable/metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
  • Vyvgart Hytrulo prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) New Formulation
    • For the treatment of adult patients with generalized myasthenia gravis or gMG who are anti-acetylcholine receptor or AChR antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy or CIDP.
  • Jobevne (bevacizumab-nwgd) Biosimilar to Avastin
    • Multiple indications as a biosimilar to Avastin - treats multiple types of cancer.
  • Opdivo + Yervoy (nivolumab + ipilimumab) Expanded indication
    • As a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC).
  • Livmarli (maralixibat)
    • For the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).
  • Valtoco (diazepam nasal spray) Expanded Indication
    • For short-term treatment of seizure clusters that are different from a person's normal seizure pattern in people 2 years of age and older.
  • Isturisa (osilodrostat) New Indication
    • As second-line treatment of endogenous hypercortisolemia in adults with Cushing syndrome.
  • Dupixent (dupilumab) New Indication
    • To treat chronic spontaneous urticaria (CSU) in adults and pediatric patients aged 12 years and older.
  • Penpulimab-kcqx (penpulimab-kcqx) 
    • In combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC).
  • Zevaskyn (prademagene zamikeracel)
    • Treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
  • Rinvoq (upadacitinib) New Indication
    • For the treatment of adults with giant cell arteritis (GCA).
  • Imaavy (nipocalimab-aahu)
    • For the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of age and older.

Make sure to sign up for alerts and stay informed on all the latest published guidelines, FDA decisions, and more!

Copyright © 2025 Guideline Central, All Rights Reserved.